Anticancer activity of anandamide in human cutaneous melanoma cells.

“Cannabinoids are implicated in the control of cell proliferation, but little is known about the role of the endocannabinoid system in human malignant melanoma. This study was aimed at characterizing the in vitro antitumor activity of anandamide (AEA) in A375 melanoma cells…

 Overall, these findings demonstrate that AEA induces cytotoxicity against human melanoma cells in the micromolar range of concentrations through a complex mechanism, which involve COX-2 and LOX-derived product synthesis and CB1 activation. Lipid raft modulation, probably linked to GPR55 activation, might also have a role.”

http://www.ncbi.nlm.nih.gov/pubmed/24041928

THC, found in cannabis, shown to be effective in the treatment of brain tumors

“In 2000, scientists at the Complutense University of Madrid carried out an extensive experiment, testing the effects of THC on cancerous brain cells in laboratory rats. Their discoveries were nothing short of amazing, as THC had effectively managed to destroy all cancer cells, while leaving healthy cells unaffected.
 
 Research into the effects of THC on glioblastoma would have had the potential to revolutionize available cancer treatments, yet due to insufficient funding and poor public exposure, the science team was unable to further their research.Manuel Guzman explained that “cannabinoids are selective antitumor compounds, as they can kill tumor cells without affecting their non-transformed counterparts.” In contrast to this, chemotherapy, the prevalent anticancer treatment of today, consists of a combination of antineoplastic drugs that have devastating physical and psychological side-effects… 
 
THC works by triggering the build-up of a chemical messenger known as ceramide, which in turn induces apoptosis (or programmed cell death) in mutated tumor cells.
Subsequent research into the properties of THC has revealed that it is among the very few naturally occurring, harmless substances that are capable of inducing programmed cell death in cancerous cells. Other substances with this property include anandamide, other cannabinoids and tumor necrosis factors produced by the immune system in its attempt to fight cancer.
 
After months of effort to obtain funding for testing the medical effects of THC on human tissues, the Madrid science team was forced to abandon this project, although there is currently no effective treatment available for malignant brain tumors.” 
 
 

The Feds Finally Recognize The Anti-Cancer Potential Of Cannabis — 36 Years Too Late!

3-24-2011: “Scientific trials have for decades documented the anti-cancer properties of cannabis and its constituents. Yet it took until this week for the website of the National Institute of Cancer, a component of the U.S. government’s National Institutes of Health, to finally acknowledged the herb’s therapeutic utility for patients living with disease or suffering from the adverse side-effects of cancer treatment.

In a newly added section to the website, entitled ‘Cannabis and Cannabinoids,’ the Institute states:

Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis and metastasis. Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.”

…The potential benefits of medicinal cannabis for people living with cancer include antiemetic effects, appetite stimulation, pain relief, and improved sleep. In the practice of integrative oncology, the health care provider may recommend medicinal cannabis not only for symptom management but also for its possible direct antitumor effect.”

It’s a stunning acknowledgment, given that the NIH is a branch of the very same government that presently maintains that the cannabis plant and all of its naturally-derived components have ‘no accepted medical use.’ Yet it also begs the question: Where has the National Institute of Cancer been all these years?

After all, the anti-tumor activity of cannabinoids were initially documented in 1975! That’s right; it’s taken 36 years for the Institute to get with the program.

Hopefully it won’t take them another 36 years to demand that the Feds finally assess whether these preclinical results are replicable in human trials.”

by Paul Armentano, NORML Deputy Director

http://blog.norml.org/2011/03/24/the-feds-finally-recognize-the-anti-cancer-potential-of-cannabis-36-years-too-late/

Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma.

Logo of cddis “Cannabinoids exert antiproliferative effects in a wide range of tumoral cells, including hepatocellular carcinoma (HCC) cells. In this study, we examined whether the PPARγ-activated pathway contributed to the antitumor effect of two cannabinoids, Δ9-tetrahydrocannabinol (THC) and JWH-015, against HepG2 and HUH-7 HCC cells. Taken together, we demonstrate for the first time that the antiproliferative action of the cannabinoids THC and JWH-015 on HCC, in vitro and in vivo, are modulated by upregulation of PPARγ-dependent pathways.”  http://www.ncbi.nlm.nih.gov/pubmed/23640460

“The antitumor activity of cannabinoids against HCC cells has been related to the ability of these drugs to induce apoptosis and autophagy. In particular, it has been previously described that cannabinoids arrest cell proliferation, reduce cell migration and inhibit angiogenesis, and therefore, cannabinoid-like compounds offer a therapeutic potential for the treatment of many types of cancer.”  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674350/

“We here illustrate that the cannabinoids THC and JWH-015 exert antitumor effect against the human HCC cell lines HepG2 and HUH-7 in vitro and in vivo through PPARγ.”  https://www.nature.com/articles/cddis2013141

Antitumor Effects of THC.

“1-Trans-[delta.sup.9]-tetrahydrocannabinol (THC) the main active component of marijuana, has been shown to exhibit anticancer activity.

Galve-Roperh et al. reported that intratumoral administration of THC induces apoptosis of transformed neural cells in culture, and also induces a considerable regression of malignant gliomas in Wistar rats and in mice… These authors suggest that their “results may provide the basis for a new therapeutic approach for the treatment of malignant gliomas.”

Thus, in our studies, rats and mice that received THC for 2 years exhibited body weight reductions, enhanced survival rates, and decreased tumor incidences in several sites, mainly organs under hormonal control.

These earlier experimental carcinogenesis results on THC clearly lend further validity to the notion that cannabinoids may indeed be anticarcinogenic.”

http://www.thefreelibrary.com/Antitumor+Effects+of+THC.-a068148345

“Antitumor effects of THC.” http://www.ncbi.nlm.nih.gov/pubmed/11097557

A Population-based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma

Logo of nihpa

“Marijuana (Cannabis sativa) contains more than 60 unique compounds known as cannabinoids. Cannabinoids, constituents of marijuana smoke, have been recognized to have potential antitumor properties. However, the epidemiological evidence addressing the relationship between marijuana use and the induction of head and neck cancer (HNSCC) is inconsistent and conflicting. An early epidemiological study reported that marijuana use was associated with an elevated risk for head and neck cancer.  However, more recent studies have failed to confirm the association of marijuana use with an increased head and neck cancer risk.

 In fact, many of these studies reported non-significant protective estimates of effect, consistent with a possible anticarcinogenic action of cannabinoids.

A recent epidemiologic review raised the need for additional, well conducted, large studies to clarify the nature of the association of marijuana use with the risk of cancer, especially head and neck cancer. In order to further elucidate the association between marijuana use and head neck cancer risk, we assessed marijuana use in detail in a population-based case-control study.

After adjusting for potential confounders (including smoking and alcohol drinking), 10 to 20 years of marijuana use was associated with a significantly reduced risk of HNSCC.

Our study suggests that moderate marijuana use is associated with reduced risk of HNSCC.”

Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma–Associated Herpesvirus-Infected Endothelium

“Kaposi sarcoma is the most common neoplasm caused by Kaposi sarcoma–associated herpesvirus (KSHV). Current treatments for Kaposi sarcoma can inhibit tumor growth but are not able to eliminate KSHV from the host. When the host’s immune system weakens, KSHV begins to replicate again, and active tumor growth ensues. New therapeutic approaches are needed.

Cannabidiol (CBD), a plant-derived cannabinoid, exhibits promising antitumor effects without inducing psychoactive side effects. CBD is emerging as a novel therapeutic for various disorders, including cancer.

In this study, we investigated the effects of CBD both on the infection of endothelial cells (ECs) by KSHV and on the growth and apoptosis of KSHV-infected ECs, an in vitro model for the transformation of normal endothelium to Kaposi sarcoma….

Cannabidiol (CBD) was first isolated in 1940. It is a major component of the plant Cannabis sativa, which is also the source of Δ9-tetrahydrocannabinol (Δ9-THC). Due to its multiple biological activities, CBD has been identified as a potential clinical agent. Moreover, CBD affects these activities without the psychoactive side effects that typify Δ9-THC. Recent studies have documented the potential antitumorigenic properties of CBD in the treatment of various neoplasms, including breast cancer, lung cancer, bladder cancer, glioblastoma,and leukemia.CBD induces these effects through a variety of mechanisms and signaling pathways

CBD has been evaluated clinically for the treatment of various conditions, including anxiety, psychosis, and pain. In contrast to other members of the cannabinoid family, CBD has a strong safety profile and induces no psychotropic effects.Therefore, it has become an attractive agent in the search for new anticancer therapies.Our current study demonstrated that CBD preferentially enhanced apoptosis and inhibited the proliferation of KSHV-infected endothelial cells. This selective targeting of KSHV-induced neoplasia suggests that CBD may have a desirable therapeutic index when used to treat cancer. Moreover, a recent study demonstrated that CBD can be delivered effectively by nasal and transdermal routes, which may be particularly valuable for the treatment of Kaposi sarcoma oral or skin lesions.”

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527984/

Cannabinoids for Cancer Treatment: Progress and Promise

Cancer Research: 68 (2)

“Cannabinoid refers to a group of chemicals naturally found in the marijuana plant Cannabis sativa L. and includes compounds that are either structurally or pharmacologically similar to Δ(9)-tetrahydrocannabinol or those that bind to the cannabinoid receptors. Although anticancer effects of cannabinoids were shown as early as 1975 in Lewis lung carcinoma, renewed interest was generated little after the discovery of the cannabinoid system and cloning of the specific cannabinoid receptors.

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of cannabinoid receptors expressed by tumor cells may offer a novel strategy to treat cancer. Here, we review recent work that raises interest in the development and exploration of potent, nontoxic, and nonhabit forming cannabinoids for cancer therapy.”

Full Text: http://cancerres.aacrjournals.org/content/68/2/339.long

Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.

“Cannabinoids (CBs) are implicated in the control of cell survival in different types of tumors, but little is known about the role of CB system in pancreatic cancer. Herein, we investigated the in vitro antitumor activity of CBs and the potential role of their receptors in human pancreatic cancer cells MIA PaCa-2…

These findings exclude the involvement of CB receptors in the regulation of MIA PaCa-2 cell growth and put AM251 forward as a candidate for the development of novel compounds worthy to be tested in this type of neoplasia.”

http://www.ncbi.nlm.nih.gov/pubmed/16500647

Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines

“Marijuana and its derivatives have been used in medicine for many centuries, and currently there is a renewed interest in the study of the therapeutic effects of cannabinoids…”

“Recently, cannabinoids (CBs) have been shown to possess antitumor properties. Because the psychoactivity of cannabinoid compounds limits their medicinal usage, we undertook the present study to evaluate the in vitro antiproliferative ability of cannabidiol (CBD), a nonpsychoactive cannabinoid compound, on U87 and U373 human glioma cell lines…”

“…the nonpsychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent.”

“In conclusion, a cannabinoid-based therapeutic strategy for neural diseases devoid of undesired psychotropic side effects could find in CBD a valuable compound in cancer therapies along with the perspective of evaluating a synergistic effect with other cannabinoid molecules and/or with other chemotherapeutic agents as well as with radiotherapy. Whatever the precise mechanism underlying the CBD effects, the present results suggest a possible application of CBD as a promising, nonpsychoactive, antineoplastic agent.”

http://jpet.aspetjournals.org/content/308/3/838.full